CAJ | 학술논문

核苷(酸)类似物(NA)已广泛用于治疗慢性乙型肝炎(CHB),而CHB需长期抗病毒治疗,病毒的不完全控制及出现耐药导致肝脏疾病进展和多重耐药越来越受到重视.NAs治疗期间监测耐药发生并根据耐药情况调整抗病毒治疗对CHB治疗具有重要意义.此文从NAs耐药发生机制、相关的耐药突变、降低耐药风险及耐药后的挽救治疗等方面进行综述.
핵감(산)유사물(NA)이엄범용우치료만성을형간염(CHB),이CHB수장기항병독치료,병독적불완전공제급출현내약도치간장질병진전화다중내약월래월수도중시.NAs치료기간감측내약발생병근거내약정황조정항병독치료대CHB치료구유중요의의.차문종NAs내약발생궤제、상관적내약돌변、강저내약풍험급내약후적만구치료등방면진행종술.
The nucleos(t)ide analogues(NAs) have been used widespreadly for chronic hepatitis B(CHB) treatment.Patients with CHB need long term antiviral therapy.It has become a critical concern to the clinical physicians because of the exacerbations in liver diseases resulting from incomplete suppression of virus replication and development of drug resistance to nucleos(t)ide analogues.Therefore,monitoring drug resistance to NAs during antiviral therapy and optimized antiviral therapy according to the viral response and drug resistance patterns is very important for CHB patients.In the article,the incidence and the patterns of NAs resistance in CHB,the reduction of NAs resistance risk and subsequent rescue therapies for NAs resistance of CHB patients are reviewed.